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Abstract: Osteoporosis is an illness which appears when the 
osteoblast/osteoclast activities are unbalanced taking place bone 
resorption (caused by osteoclasts) in higher extension than bone 
formation (induced by osteoblasts). Alendronate is one of the most 
used drugs for osteoporosis treatment despite its scarce 
bioavailability. Here we present the synthesis and characterization of 
mesoporous gated nanoparticles (two sets) for the controlled release 
of alendronate. The first set of nanoparticles (S1) were loaded with 
sulforhodamine B and capped with a peptide that could be 
selectively hydrolyzed by cathepsin K enzyme (overexpressed in 
osteoclasts). The second set (S2) was functionalized with 
aminopropyl moieties, loaded with nitrobenzofurazan labelled 
alendronate and capped with the same peptide. Both nanoparticles 
were internalized by RAW 264.7 macrophages (which could 
differentiate in osteoclasts) and were able to release its entrapped 
cargo in the presence of cathepsin K added in the macrophage 
lysates. Using S2 nanoparticles 4.2% of the total alendronate 
amount in contact with the cells is liberated inside them and could 
produce its therapeutic effect. 
Introduction 
Osteoporosis is an illness characterized by producing a systemic 
skeletal disorder, which results in a reduction of bone strength, 
an increase in susceptibility to fractures and skeletal fragility and 
an interruption of the bone micro architecture. Osteoporosis 
appears when the osteoblast/osteoclast activities are 
unbalanced taking place bone resorption (caused by 
osteoclasts) in higher extension than bone formation (induced by 
osteoblasts). Osteroporosis is widespread and it is a major 
problem, either from the economic and healthcare point of view, 
as it affects 1 in 2 women and 1 in 5 men. At present there are 
multiple therapeutic options available for osteoporosis treatment 
[1] but the use of oral bisphosphonates is the first choice because 
of the accumulated experience in their use and their price. 
Among bisphosphonates, alendronate is the most used drug. [2] 
Its mechanism of action has been linked to the induction of 
apoptosis in osteoclasts and thus the reduction of osteoclast-
mediated bone resorption.[3] Despite its widespread use, 
alendronate has one major drawback: a scarce 0.67% 
bioavailability.[4] 
On the other hand, the use of nanomaterials for drug delivery 
has demonstrated to be an appropriate alternative for improving 
drug bioavailability.[5] Combination of nanomaterials with drugs 
can lead to nanoformulations which improved active compound 
bioavailability and also allowed, in certain cases, controlled 
release of the cargo. Micelles, liposomes, organic polymers, 
dendrimers and inorganic nanoparticles are the most common 
used supports to prepare active nanoformulations.[6] Among 
them, mesoporous silica nanoparticles have attracted great 
attention due to their remarkable features such as inertness, 
biocompatibility, pores in the 2-3 nm range (which allowed the 
loading of high amounts of cargo), high specific volume and 
easy functionalization using the well-known alkoxysilane 
chemistry (which allowed the grafting of selected molecules 
acting as targeting ligands or as capping ensembles).[7] Taking 
into account the above cited properties, mesoporous silica 
nanoparticles have been extensively used for the storage and 
release of highly hydrophobic drugs in several pharmaceutical 
applications.[8] In fact, mesoporous silica scaffolds have already 
been used for the controlled release of alendronate in order to 
overcome its poor water solubility. [9] 

















































Figure 1. Design and controlled release performances of S1 and S2 nanoparticles. 
 
Going a step further in controlled drug delivery nanodevices, the 
use of mesoporous materials functionalized on its external 
surface with capping ensembles and loaded with selected drugs 
allows the synthesis of new and more efficient pharmaceutical 
formulations.[10] In these materials the presence of the bulky 
capping ensemble (such as a supramolecular complex or 
selected biomolecules such as peptides, oligosaccharides or 
DNA/RNA fragments) inhibits cargo release. However, under 
application of external stimuli, the charge, size and/or shape of 
the gating ensemble changes and, as a consequence, the steric 
crowding around pore outlets is reduced enabling cargo release. 
[11] Besides, it has been well established that these gated 
nanomaterials can be internalized by cells through phagocytosis 
or endocytosis processes.[12] Once the material is inside the cell, 
if a stimulus able to modify the capping ensemble is present, the 
drug is released. In addition, when this stimulus is only present 
in one type of cells, the opening of the gate will take place 
selectively in these specific cells. 
Taking into account the above mentioned facts and our interest 
in the development of gated materials with applications in 
controlled release protocols, [13] we present herein the synthesis 
and controlled release behavior of peptide-capped mesoporous 
silica nanoparticles for the selective controlled release of 
alendronate. For this purpose, the pores of the mesoporous 
silica nanoparticles were loaded with an alendronate derivative, 
containing nitrobenzofurazan chromophore in order to evaluate 
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its release using UV-visible measurements, and the external 
surface was functionalized, using an alkyne-azide “click” 
coupling reaction, with a peptide able to be hydrolyzed by 
cathepsin K enzyme. Cathepsin K is a proteolytic enzyme that is 
expressed in osteoclasts and multinucleated giant cells [14] and is 
also able to preferentially hydrolyze specific amide bonds in 
some peptides.[15] The prepared materials are depicted in Figure 
1 (S1 and S2 loaded with sulforhodamine B and with the 
derivatized alendronate respectively). It was expected that the 
presence of a bulky peptide grafted onto the external surface of 
the nanoparticles inhibited cargo release whereas in the 
presence of cathepsin K a marked payload delivery should be 






































Figure 2. PXRD patterns of (a) as-synthesized MCM-41 nanoparticles; (b) calcined MCM-41 nanoparticles; (c) S1; (d) S2
Results and Discussion 
Design and synthesis of gated materials 
 
Two gated nanoparticles were prepared, S1 loaded with 
sulforhodamine B and S2 loaded with an alendronate derivative. 
For the synthesis of both materials, mesoporous silica 
nanoparticles (prepared using cetyltrimethylammonium bromide 
as structure directing agent and tetraethylorthosilicate as silica 
source)[16] were used. Then, for S1, the pores of the inorganic 
scaffold were loaded with sulforhodamine B and then the 
external surface functionalized with (3-
azidopropyl)triethoxysilane. Finally, the external surface was 
decorated with a selected peptide (ác. Pentinoico)-NH-
KEFSFRLKEGEFSFRLKEGEFSFRLK-Ac using an alkyne-azide 
“click” coupling reaction. The selection of the peptide was based 
on data in the literature that indicated that this sequence could 
be selectively (or in a major extension) hydrolyzed in presence 
of cathepsin K when compared with other enzymes of the 
cathepsin series [27]. On the other hand, S2 material was 
prepared using a slightly modified procedure. In a first step, 
alendronate was labelled with 4-chloro-7-nitrobenzofurazan 
yielding a derivative containing NBD chromophore (NBD-
alendronate) with absorption bands at 475 (ε= 19500 M-1 cm-1) 
and 350 (ε= 8160 M-1 cm-1) nm[17] (see figure S1 in the 
supporting information). In a second step, the mesoporous silica 
nanoparticles were decorated with aminopropyl moieties (mainly 
onto the inner of the pores but certain external surface 
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functionalization could not be discarded) in order to impart the 
inner surface with positive charge which facilitates NBD-
alendronate loading.[9] Then, the pores were loaded with NBD-
alendronate and the external surface was decorated with 
azidopropyl moieties. Finally, solid S2 was prepared after the 
grafting of selected peptide using an alkyne-azide “click” 
coupling reaction. 
 
Characterization of the prepared materials 
 
The as-made MCM-41 nanoparticles, calcined solid, S1 and S2 
were characterized using powder X-ray diffraction (PXRD), 
transmission electron microscopy (TEM), N2 adsorption-
desorption isotherms, elemental analysis, DLS and zeta 
potential measurements. PXRD patters of as made and calcined 
MCM-41 nanoparticles showed the four mesoporous 
characteristic low-angle peaks (100), (110), (200), (210) 
corresponding to a hexagonal-ordered array (see Figure 2). 
Besides, as expected, the MCM-41 calcined nanoparticles 
present a significant shift of (100) reflection due to the cell 
contraction induced by the condensation of silanol groups during 
the calcination process. On the other hand, S1 and S2 show 
lower PXRD signal intensities when compared to the parent 
silica (see also Figure 2). The intensity decrease is clearly 
appreciated in the most intense (100) reflection, being especially 
important in S2. However, PXRD pattern of S1 still preserve two 
additional (110) and (200) reflections of lower intensity, while in 
the case of S2 all signals disappear (in the background of the 
spectra) with the exception of the (100) peak. This behavior, is 
most likely due to the contrast lowering between the pore walls 
and the pore voids that must occurs after the 
loading/functionalization process. The fact that it is more 
pronounced for S2 than for S1 and can be associated with two 
factors, the functionalization of S2 with aminopropyl moieties 
(with a high proportion located in the inner of the pores) and 
probably with a higher charge of alendronate than of 
sulforhodamine B in S1. Nevertheless, the preservation in both 
materials (S1 and S2) of the (100) reflection in the PXRD 
patterns strongly evidences that the mesoporous scaffold is 
































Figure 3. Representative TEM images of (a,b) S1 and (c,d) S2 nanoparticles. Inset  in a) and c) particles size distribution. 
 
On the other hand, TEM images in Figure 3 show that the 
morphology of both samples, S1 and S2, can be described as 
relatively dispersed spherical particles. We achieve, in both 
cases, a high homogeneity in particle sizes (see insets in Figure 
3), with averaged diameters of 117 and 172 nm for S1 and S2, 
respectively. Furthermore, TEM images confirm, as expected 
according to PXRD data, the presence of mesopores (as white 
spots, appreciated in the high magnification images in Figures 
3b and 3d). These white spots are more visible in the case of S1 
than in S2. This fact probably is due to a combination of two 
factors: the relatively higher values of particle size and loading 
(see below) in the case of S2. 
The amount of loaded sulforhodamine B in S1 (0.98 mg/ 100 mg 
solid) was measured by fluorescence after nanoparticles 
disaggregation in concentrated NaOH (see figure S2 in the 
supporting information). Besides, the amount of phosphorus in 
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S2 nanoparticles was measured by ICP coupled with mass 
spectrometry. The phosphorus determined accounted for the 
amount of NBD-alendronate loaded into the pores of S2 
nanoparticles (8.23 mg/100 mg solid). On the other hand, the 
organic matter grafted onto the external surface of S1 and S2 
was evaluated by elemental analysis and the obtained values 
are included in Table 1. From these data, it can be deduced that 
the lower size of the labeled alendronate compared to the 
sulforhodamine B, along with the electrostatic interaction 
between alendronate anions and the protonated propilamine 
groups, are factors that work in a cooperative way to significantly 
increase the drug loading when compared to sulforhodamine B 
incorporation. These data correlate with the previous 
characterization through PXRD and TEM. Finally, a similar 
functionalization degree (preferently on the external surface of 
the particles) has been achieved for S1 and S2. This could be 
related with the similar size of the S1 and S2 particles. The 
slightly higher value of organic material bounded to the silica 
surface in the case of S2 (despite its larger size) must be 
associated with the functionalization with propylamine groups, 
that also can be incorporated in a certain proportion inside the 
mesopores. 
 
Table 1. Data of cargo inside the nanoparticles and organic material outside the pores 
 






































S1 0.98 39 375 0.13 2.00 0.32 > 100 
S2 8.23 42
[a]
 113 0.02 - 0.37 > 100 
[a] Include both the peptide that acts as molecular gate and the amine used in the amination reaction. [b] Values determined by application of the BJH model on 
the adsorption branch of the isotherms. 
 
The shape of the N2 adsorption-desorption isotherms shown in 
Figure 4 is typical of mesoporous silica materials with restricted 
access to the mesopores. The typical adsorption step at 
intermediate relative partial pressure values (associated to the 
filling of the surfactant generated mesopores) which is still 
visible for the S1 solid, practically disappears in the case of the 
S2 material. This difference can be quantified from the data 
gathered in Table 1. The low BET surface area and the absence 
of mesopore volume in the case of S2 indicates that the only 
accessible surface for the N2 must be the external shell of the 
particles. This fact is consistent with the presence of a double 
organic functionalization and the high alendronate loading. In the 
case of S1, the lower dye charge and the simple 
functionalization still leave some accessibility to the interior of 
the mesopores. This results in higher BET area and BJH 
mesopore volume. On the other hand, a similar textural (inter-
particle) porosity is observed in both cases as consequence of 
the packing of silica spheres with similar size. The slightly higher 
textural pore volume measured for S2 when compared to S1, 
could be due to two factors: the larger size of the S2 particles 
(leading to a larger size of the inter-particle macropores) and to 
the existence of a more pronounced trend towards aggregation 
(see below). 
Figure 4. N2 adsorption desorption isotherms of samples (a) S1 and (b) S2. 
In order to evaluate the dispersibility of S1 and S2 nanoparticles, 
a protocol including ultrasound irradiation and posterior filtration 
was optimized. Without this treatment in both cases we observe, 
through DLS, the presence of a certain amount of large 
aggregates of ca. 2 µm. However, after our optimized procedure 
the size of the grains decreases in a marked way up to ca. 122 
and 350 nm for samples S1 and S2, respectively. In the case of 
S1, this value fits very well with the average diameter 
determined through TEM. Hence, we can assume that the 
dispersion of the S1 sample is complete in the form of isolated 
particles. On the contrary, some aggregation occurs for S2. The 
size of the grains measured by DLS is ca. 2-fold of the particle 
diameter estimated by TEM. This fact is indicative of a relatively 
low aggregation degree of the individual nanoparticles 
compatible with a mixture of isolated particles and small clusters 
formed from two or three particles. This different tendency 
towards aggregation must be associated with the organic groups 
located at the external surface of the particles. We have 
measured the values of the ζ-potential for S1 (-15.7 mV) and S2 
(-6.4 mV) samples in water. The decrease in the ζ-potential 
value in S2 could be due to the functionalization with 
aminopropyl groups which, being partially protonated at neutral 
pH, diminish the negative surface charge of the silica, leading to 
a more favorable aggregation. 
 
Controlled release studies 
 
In a first step the ability of the peptide-based molecular gates to 
keep the cargo inside the pores was evaluated by comparing 
dye liberation in both S1 and the corresponding uncapped 
nanoparticles loaded with sulforhodamine B under the same 
conditions with. Dye liberation in the latter material was 
practically instantaneous whereas in S1 a constant 
concentration of the dye in solution was achieved after around 
3.5 hours (see figure S3 in the supporting information). 
On the other hand, taking into account the fact that the gating 
peptide is composed by amino acids containing different pH-
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sensitive functional groups, the controlled release performances 
of S1 was tested at different pH values (5.5, 7.0, 7.4, 7.8 and 
8.0) in DMEM. For this purpose, DMEM suspensions of S1 at 
selected pH values were kept at room temperature for 24 h, time 
enough for the total dye liberation. Then, solid was centrifuged 
and the sulforhodamine B emission at 590 nm (excitation at 565 
nm) in the solution measured. The obtained results showed 
moderate sulforhodamine B release from S1 nanoparticles at 
slightly acidic (pH 5.5) and basic (pH 7.8 and 8.0) environments 
(see figure S5 in the supporting information). The smaller 
sulforhodamine B release was observed when S1 nanoparticles 
were suspended in DMEM at pH 7.4 in which a concentration of 
fluorophore of 1.9 x 10-6 M (54% of the entrapped cargo was 
released) was reached (calculated using a calibration curve, see 
Supporting Information). Then, the release of sulforhodamine B 
from S1 nanoparticles at pH 7.4 in the presence of cathepsin K 
(2µL enzyme solution prepared from 25 µg of cathepsin K in 100 
µl sodium acetate/acetic acid buffer 50 mM) was also evaluated. 
The obtained results (Figure 5) show the emission intensity of 
the released sulforhodamine B from S1 in the absence and in 
the presence of cathepsin K after 24 h (see figures S3 and S4 in 
the supporting information for time dependent liberation and 24 
h fluorescence spectra). As could be seen, an increase in 
sulforhodamine B release in the presence of enzyme was 
observed. Using a calibration curve the amount of 
sulforhodamine B released was 2.8 x 10-6 M (79.5 % of the 
entrapped fluorophore which was ca. 1.5-fold higher than the 
release observed in the absence of stimuli). The observed 
increase in sulforhodamine B release could be ascribed to 
cathepsin K-induced hydrolysis of the grafted peptide. To 
establish the specificity of cathepsin K in the opening 
mechanism control release studies with S1 and pronase enzyme 
were carried out. In these studies, pronase was unable to induce 
the hydrolysis of the capping peptide and the same 
sulforhodamine B release was observed for S1 in the absence 

















Figure 5. Sulforhodamine B released (emission at 590 nm, excitation at 565 
nm) from S1 suspensions in DMEM at pH 7.4 in the absence and in the 
presence of cathepsin K after 24 h. Data presented as mean ± SD (n=3). 
**p<0.01 vs. blank (Student’s test). 
 
Controlled release studies in cells 
 
In a first step, the viability of the peptide capped nanoparticles 
without loadings in RAW 264.7 macrophages was tested. RAW 
264.7 macrophages were tested because there are several 
experimental protocols to differentiate in osteoclasts.[18] MTT 
assays showed the non-toxicity of nanoparticles at different 
concentrations (50, 100 and 200 µg/ml) and after 24 and 48 h 
(data not shown). 
Then, in a second step, the internalization and controlled release 
performance of S1 in RAW 264.7 macrophages was tested. For 
this purpose, RAW 264.7 macrophages were seeded in 6 well 
plates (2.0 x 106 cell/well) and maintained overnight in 
DMEM/F12 medium containing 10% foetal calf serum and 1% 
penicillin/streptomycin. Then, cells were washed with fresh 
medium and treated with S1 (30 µg/ml) for 24 h. After further 
washing with PBS, to eliminate not internalized particles, cells 
were lysed with 300 µl of buffer A (10 mM HEPES, 1 mM EDTA, 
1 mM EGTA, 10 mM KCl, 1 mM DTT, 5 mM NaF, 1 mM Na3VO4, 
10 mM Na2MoO4, 1 μg/ml leupeptin, 0,1 μg/ml aprotinin, and 0,5 
mM PMSF) during 10 min. The cellular lysate from each well 
was centrifuged (3000xg, 10 min) and the supernatant was 
transferred and DMEM was added until a total volume of 6 mL 
was reached. This solution was then divided in two 3 mL 
portions. One of them was treated with cathepsin K whereas the 
other remained untreated. Finally, sulforhodamine B emission in 
the lysates was evaluated by measuring ints emission at 590 nm 
(excitation at 565 nm). All the experiments were carried out 
three times and the average emission value was obtained. 















Figure 6. Sulforhodamine B (emission at 590 nm, excitation at 565 nm) 
presented in the lysates of RAW 264.7 macrophages treated with S1 in the 
absence (blank) and in the presence of cathepsin K (enzyme). Data presented 
as mean ± SD (n=3). **p<0.01 vs. blank (Student’s test). 
 
As could be seen in Figure 6, in the lysates without cathepsin K 
a moderate sulforhodamine B release was observed (0.21 x 10-6 
M calculated using a calibration curve). Assuming that 
sulforhodamine B released from S1 in the lysates is the same 
than in the experiments carried out in DMEM (54%) an intake of 
nanoparticles by RAW 264.7 macrophages of 5.4% was 
calculated. However, a marked sulforhodamine B release in the 
lysate treated with cathepsin K was observed. The concentration 
of sulforhodamine B in the lysate fraction treated with the 
enzyme was 0.76 10-6 M (ca. 3.6-fold enhancement). Taking into 
account the same nanoparticle intake (5.4%) it could be 
estimated that more than 95% of the entrapped sulforhodamine 
B was released. These indirect experiments showed that S1 
nanoparticle were properly endocytosed by RAW 264.7 
macrophages and subsequent addition of cathepsin K to cell 
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lysates induced the hydrolysis of the capping peptide with 
subsequent pore opening and sulforhodamine B release. 
Going a step further we decided to study the controlled release 
features of S2 nanoparticles (loaded with NBD-alendronate) 
under similar conditions. Again, RAW 264.7 macrophages were 
seeded in 6 well plates (2.0 x 106 cell/well) and maintained 
overnight in DMEM/F12 medium containing 10% foetal calf 
serum and 1% penicillin/streptomycin. Then, cells were washed 
with fresh medium and treated with S2 (30 µg/ml) during 24 h. 
After further washing with PBS, to eliminate not internalized 
particles, cells were lysed with 300 µl of buffer A during 10 min. 
The cellular lysate from each well was centrifuged, the 
supernatant was transferred and DMEM was added until a total 
volume of 6 mL was reached. This solution was then divided in 
two 3 mL portions. One of them was used as blank and the other 
was treated with cathepsin K. Then, the NBD-alendronate 
released was monitored by measuring the absorption band of 
the chromophore at 350 nm (see Figure 7). As could be seen in 
Figure 7, the lysate fraction without enzyme showed a very small 
absorption indicative of nearly a negligible NBD-alendronate 
release. However, a marked NBD-alendronate was observed 
when lysate was treated with cathepsin K (2.68 10-6 M using an 
UV-visible calibration curve). Taking into account that both 
nanoparticles were functionalized with the same peptide and its 
size and external covering are quite similar, a comparable 
uptake by RAW 264.7 macrophages could be expected. Then, 
assuming an intake of 5.4% it can be determined that the 

















Figure 7. NBD absorption at 350 nm (from the NBD-alendronate released) 
presented in the lysates of RAW 264.7 macrophages treated with S2 in the 
absence (blank) and in the presence of cathepsin K (enzyme). Data presented 
as mean ± SD (n=3). ***p<0.01 vs. blank (Student’s test). 
 
Finally, taking into account the fact that we could calculate the 
total amount of NBD-alendronate in S2 nanoparticles 
administered to RAW 264.7 macrophages and the concentration 
of the labelled drug in the lysates (from the corresponding 
calibration curve), we estimated that 4.2% of the total 
alendronate amount in contact with the cells has been liberated 
inside them and could produce its therapeutic effect. Taking into 
account that it has been reported that bioavailability of different 
drugs increases when they are encapsulated in mesoporous 
silica nanoparticles and that S2 is able to go inside the cells and 
liberate there the labeled alendronate, we think that S2 presents 
promising properties for increasing the efficiency of 
osteroporosis treatment with alendronate. 
Conclusions 
Two new nanodevices, based MCM-41 mesoporous silica 
nanoparticles, loaded with sulforhodamine B (S1) and with a 
NBD-labelled alendronate (S2) and capped with the peptide (ác. 
Pentinoico)-NH-KEFSFRLKEGEFSFRLKEGEFSFRLK-Ac 
(which is selectively hydrolyzed by cathepsin K enzyme 
presented in osteoclasts) have been prepared and fully 
characterized. Controlled release studies, carried out with S1 in 
DMEM at pH 7.4, showed that cathepsin K was able to 
hydrolyze the peptide allowing sulforhodamine B release. 
Besides, both solids were properly internalized by RAW 264.7 
macrophages and were able to release its entrapped cargo after 
adding cathepsin K to the lysates obtained after treatment with 
nanoparticles. 4.2% labelled alendronate was present in the 
cathepsin K treated cells. We believe that these nanodevices 
could be the basis for the development of novel 
nanoformulations for an effective alendronate release in 
osteoporosis treatments.  
Supporting Information Summary 
Experimental section, synthesis of materials, characterization 
and liberation studies. 
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We describe nanoparticles S1 and S2 that were loaded with sulforhodamine B and alendronate and capped with a peptide that could 
be selectively hydrolyzed by cathepsin K enzyme Both nanoparticles were internalized by RAW 264.7 macrophages and were able to 
release its entrapped cargo in the presence of cathepsin K added in the macrophage lysates. Using S2 nanoparticles 4.2% of the 
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